Different protective effects of tauroursodeoxycholate, ursodeoxycholate, and 23-methyl-ursodeoxycholate against taurolithocholate-induced cholestasis
- 20 Downloads
The coinfusion of tauroursodeoxycholate (TUDC) prevents taurolithocholate (TLC) -induced cholestasis. 23-Methyl-ursodeoxycholate (MUDC) is a side-chain derivative of ursodeoxycholate (UDC). If conjugation with taurine is important for the protective effect of UDC, then MUDC may not be as able as TUDC to prevent TLC-induced cholestasis since it is poorly amidated by the liver. To answer this question, isolated livers of adult Sprague-Dawley rats were coinfused with MUDC (UDC, TUDC) and TLC. After 15 min, inflow rates of the bile acids were doubled. In further experiments taurine in excess was added to the coinfused bile acids. The uptake of bile acids was >90% in all groups, irrespective of whether they were perfused alone or in combination. Single perfusion of TLC caused a rapid decrease in bile flow. UDC and MUDC were hypercholeretic; TUDC moderately choleretic. During coinfusion experiments, TUDC not only completely abolished cholestasis but in addition increased bile flow and biliary bile acid secretion. UDC did prevent TLC cholestasis at the lower inflow rates. At high inflow rates, bile flow decreased significantly. Addition of taurine to this bile acid combination did not significantly improve the anticholestatic effect of UDC. At low and high infusion rates of MUDC, cholestasis induced by TLC was reduced very little. Cumulative bile flow over 30 min fell by ≈70% as compared to that of singly perfused MUDC. Addition of taurine to the coinfused MUDC/TLC slightly, but significantly, improved the anticholestatic effect of MUDC. Since MUDC is by far less protective than UDC (and TUDC) despite similar physicochemical properties, it is concluded that taurine conjugation of UDC seems to be a prerequisite to prevent TLC-induced cholestasis. The results imply that treatment of cholestatic liver diseases with taurine-conjugated UDC might be more appropriate than with unconjugated UDC in cases where taurine conjugation is defective or where taurine depletion has occurred.
Key wordsursodeoxycholate bile acid coinfusion bile acid metabolism isolated liver perfusion cholestasis
Unable to display preview. Download preview PDF.
- 2.Bellentani S, Tabarroni G, Barchi T, Ferretti I, Fratti N, Villa E, Manenti F: Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gammaglutamyltranspeptidase serum levels in patients with hyerptransaminaseemia—results from a double-blind controlled trial. J Hepatol 8:7–12, 1989PubMedGoogle Scholar
- 3.Bateson MC, Ross PE, Diffey BL: Ursodeoxycholic acid in primary biliary cirrhosis. Lancet 1:898–899, 1989Google Scholar
- 5.Roda A, Grigolo B, Aldinin R, Simoni P, Pellicciari R, Natalini B, Balducci R: Bile acids with a cyclopropyl-containing side chain. 4. Physicochemical and biological properties of the four diastereoisomers of 3α,7β-dihydroxyd-22,23-methylene-5β-cholan-24-oic acid. J Lipid Res 28:1384–1397, 1987PubMedGoogle Scholar
- 7.Castagnola V, Frigerio G, Pelicciari R, Roda A: New derivatives of bile acids, process for the production thereof corresponding pharmaceutical compositions. European Patent 135:782 A2, 1984Google Scholar
- 9.Schölmerich J, Kitamura S, Baumgartner U, Miyai K, Gerok W: Taurohyocholate, taurocholate and tauroursodeoxycholate but not tauroursocholate and taurodehydrocholate counteract effects of taurolithocholate in rat liver. Res Exp Med 190:121–129, 1990Google Scholar
- 15.Güldütuna S, Zimmer G, Imhof M, Bhatti S, You T, Leuschner U: Molecular aspects of membrane stabilization by urosdeoxycholate. Gastroenterology 104:1736–1744, 1993Google Scholar
- 30.Zouboulis-Vafiadis I, Dumont M, Erlinger S: Hypercholeretic bile acids. Hepatic metabolism and effect on bile secretion of 23-methyl-ursodeoxycholic acid.In Bile Acids and the Liver. Paumgartner G, A Stiehl, W Gerok (eds). Lancaster, MTP Press Limited, pp 195–197, 1986Google Scholar